摘要
Objective: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. Here, we revealed a novel mechanism by which OCA improves NAFLD by affecting hepatic long-chain fatty acids (LCFAs) uptake. Methods: Stably transfected HEK-293 cells expressing fatty acid transport protein 5 (FATP5) were established to examine fatty acid uptake; FXR-/-, human (h) FATP5, and FXR-/-/hFATP5 mouse models were incorporated to explore the effects of OCA on FATP5 ex vivo and in vivo. Results: OCA inhibited hFATP5 (IC50 =0.07 mu M) more than murine (m) FATP5 (IC50 =1.04 mu M) as measured by LCFAs uptake in FATP5 expressing HEK-293. OCA also inhibited LCFA uptake in primary hepatocytes from hFATP5 mice, FXR-/-/hFATP5 mice more than that from FXR(-/-)mice, ex vivo. Moreover, OCA inhibited LCFAs uptake by livers in hFATP5 mice and FXR-/-/hFATP5 mice, but not in FXR-/- mice, in vivo. Long-term administration of 0.04% OCA markedly reduced hepatic triglyceride (TG) accumulation in hFATP5 mice and FXR-/-/ hFATP5 mice by 63% and 53%, respectively, but not in FXR-/- mice. Conclusions: OCA ameliorated high-fat diet-induced NAFLD independent of FXR by inhibiting hepatic hFATP5mediated LCFAs uptake. This suggests that the therapeutic effects of OCA on NAFLD in vivo are mediated by a novel, hFATP5 dependent mechanism.
學科與關鍵詞
- Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD MiceLin, Chuangzhen; Yu, Bingqing; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*Frontiers in Pharmacology, 2022, 13: 880508.被引 5
- Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver DiseaseLu, Huanfen; Ban, Zhenglan; Xiao, Kai; Sun, Madi; Liu, Yongbo; Chen, Fangman; Shi, Tongfei; Chen, Li; Shao, Dan*; Zhang, Ming*; Li, Wei*Advanced Science, 2024.
- Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitisCao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun*; Wang, Yan*European Journal of Medicinal Chemistry, 2022, 230: 114089.被引 9
